©2022 Stanford Medicine
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
Trial ID: NCT03859700
Open-label, follow-up study for subjects who completed the EPITOPE study.
EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children
- completion of the EPITOPE study
- Generalized dermatologic disease (for example, active atopic dermatitis, uncontrolled
generalized active eczema, ichthyosis vulgaris) extending widely on the skin and
especially on the back or arms with no intact zones to apply the Viaskin patches.
- Diagnosis of asthma that evolved to severe, unstable or uncontrolled asthma
biological: DBV712 250 mcg
School of Medicine
300 Pasteur Drive
Stanford, CA 94305